Ensysce Biosciences (ENSC) Net Cash Flow Growth (1y) (2019 - 2025)
Ensysce Biosciences (ENSC) Net Cash Flow Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -113.33% |
| Jun 30, 2025 | 64.38% |
| Mar 31, 2025 | -119.71% |
| Dec 31, 2024 | -91.19% |
| Sep 30, 2024 | 231.51% |
| Jun 30, 2024 | -197.82% |
| Mar 31, 2024 | 231.69% |
| Dec 31, 2023 | 74.86% |
| Sep 30, 2023 | -407.78% |
| Jun 30, 2023 | 151.29% |
| Mar 31, 2023 | 54.71% |
| Dec 31, 2022 | -125.01% |
| Sep 30, 2022 | 165.90% |
| Jun 30, 2022 | -160.95% |
| Mar 31, 2022 | -11,612.91% |
| Dec 31, 2021 | -97.04% |
| Sep 30, 2021 | 99.36% |
| Jun 30, 2021 | -95.80% |
| Mar 31, 2021 | 103.72% |
| Dec 31, 2020 | 86,046.89% |